Jonathan Hau

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

James J. Crawford, Adam R. Johnson, Dinah Misner et al. · Journal of Medicinal Chemistry · 2018 · 240 citations · Full text

Tyrosine Kinase, Immunology, Biological Therapy +24

Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell–associated damage in IFNα-driven lupus nephritis

Arna Katewa, Yugang Wang, Jason A. Hackney et al. · JCI Insight · 2017 · 72 citations · Full text

A rational approach towards development of amorphous solid dispersions: Experimental and computational techniques

Paroma Chakravarty, Joseph W. Lubach, Jonathan Hau et al. · International Journal of Pharmaceutics · 2017 · 40 citations

Materials Science, Materials Engineering, Engineering +11

In Vitro and In Vivo Evaluation of Amorphous Solid Dispersions Generated by Different Bench-Scale Processes, Using Griseofulvin as a Model Compound

Po‐Chang Chiang, Yong Cui, Yingqing Ran et al. · The AAPS Journal · 2013 · 32 citations · Full text

Materials Science, Engineering, Excipients +7

Investigation of the Rat Model for Preclinical Evaluation of pH-Dependent Oral Absorption in Humans

Joseph W. Lubach, Jacob Z. Chen, Jonathan Hau et al. · Molecular Pharmaceutics · 2013 · 32 citations

Mefenamic Acid, Pharmacotherapy, Experimental Pharmacology +17